Harrow (HROW) Other Working Capital Changes (2010 - 2026)
Harrow's (HROW) quarterly Other Working Capital Changes came in at -$111000.0 in Q3 2024, down 628.57% year-on-year from $21000.0 in Q4 2023, and down 181.62% quarter-over-quarter from $136000.0 in Q2 2024.
Harrow (HROW) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Harrow's Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$111000.0 for Q3 2024.
- On a quarterly basis, Other Working Capital Changes fell 628.57% year-over-year to -$111000.0 in Q3 2024; TTM through Sep 2024 was -$16000.0, a 142.11% decrease from a year earlier, with the FY2023 full-year figure at -$38000.0, down 139.18% from the prior year.
- Other Working Capital Changes declined to -$111000.0 in Q3 2024 per HROW's latest filing, from $136000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $5.1 million in Q4 2024 and bottomed at -$4.1 million in Q4 2023.
- The 5-year median for Other Working Capital Changes is $101000.0 (2025), against an average of $460058.8.
- Across the five-year window, Other Working Capital Changes soared 857.14% in 2021 and sank 3800.0% in 2023, its largest moves.
- Year by year, Other Working Capital Changes stood at $3000.0 in 2020, then surged by 333.33% to $13000.0 in 2021, then slumped by 115.38% to -$2000.0 in 2022, then sank by 3800.0% to -$78000.0 in 2023, then plunged by 42.31% to -$111000.0 in 2024.
- Per Business Quant, the three latest HROW Other Working Capital Changes figures stand at -$111000.0 (Q3 2024), $136000.0 (Q2 2024), and $37000.0 (Q1 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -639,000.00 |
| Mar 31, 2026 | -639,000.00 |
| Mar 31, 2026 | -639,000.00 |
| Dec 31, 2025 | 1.53 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Jun 30, 2025 | -54,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 5.09 Mn |
| Dec 31, 2024 | 5.09 Mn |
| Dec 31, 2024 | 5.09 Mn |
| Sep 30, 2024 | 810,000.00 |
| Sep 30, 2024 | 810,000.00 |